VN

Vidya Nidhi

Active Director Director DIN 09585436
DIN 09585436 First appointment Apr 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value •••• Premium profile

About Vidya Nidhi

Data last updated:

Vidya Nidhi is a Director at Grepso Pharmaceutical Private Limited (since 2022). The company operates in Pharma. Grepso Pharmaceutical Private Limited reported revenue of ₹8.9 Lakh (FY 2025).

DIN 09585436
Primary Designation Director
Industry Pharma
First Appointment 26 Apr 2022
Oldest Company Age 4 yrs
Largest company Grepso Pharmaceutical Private Limited · ₹8.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Apr 20222022₹8.9 Lakh (FY 2025)Active

Board colleagues of Vidya Nidhi

NameDINCompanyDesignation
Puspa Kumari09585435Grepso Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Grepso Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Vidya Nidhi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vidya Nidhi

Vidya Nidhi currently holds 1 directorship: Grepso Pharmaceutical Private Limited (Director, since 26 Apr 2022, revenue ₹8.9 Lakh (FY 2025)).

Vidya Nidhi was first appointed on 26 Apr 2022 as Director at Grepso Pharmaceutical Private Limited.

The current boards of Vidya Nidhi's companies include Puspa Kumari (Grepso Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available